Buy & Sell Roundhill Russell 2000 0DTE Covered Call Strat ETF (RDTE) – Roundhill Russell 2000 0DTE Covered Call Strat ETF Price Today
Key Stats
- -Market Cap
- Income / Options OverlaySector
- -10.69%3M Drawdown
- -Enterprise Value
- -Dividend Yield
- 17 daysTypical Hold Time
Over the past 52 weeks, Roundhill Russell 2000 0DTE Covered Call Strat ETF has traded between a low of $26.4 and a high of $34.73, highlighting its annual price range. Over the past three months, Roundhill Russell 2000 0DTE Covered Call Strat ETF has recorded a drawdown of -10.69%, reflecting recent price volatility. On average, investors hold Roundhill Russell 2000 0DTE Covered Call Strat ETF for approximately 17 days, indicating typical investor behavior on the platform.
About Roundhill Russell 2000 0DTE Covered Call Strat ETF
RDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the Russell 2000 Index. The fund primarily holds a portfolio of short-term U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the Russell 2000. This highly tactical strategy aims to maximize premium capture by exploiting the high time decay of options that are expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Most Recent News
ExxonMobil warns oil prices could spike to $160/barrel amid low inventories and geopolitical tensions.
ExxonMobil's Senior Vice President Neil Chapman warned that crude oil prices could surge to $150-$160 per barrel soon due to critically low inventory levels, despite recent price drops linked to U.S.-Iran peace talks. The company highlighted that str...

XRP shows signs of bottoming as smart money accumulates and ETFs hit best month of 2026.
XRP has shown signs of bottoming after a five-month consolidation, with smart money investors increasing accumulation. XRP ETFs recorded their best month in 2026, adding $131 million in inflows in May, contrasting with declines in Bitcoin and Ethereu...

Whitehawk reveals SEZ6 as a promising target for new cancer drug HWK-206, advancing to clinical trials in 2026.
Whitehawk Therapeutics announced data showing SEZ6 protein is highly expressed in small cell lung cancer (SCLC) and other neuroendocrine tumors, exceeding other known targets. This supports their development of HWK-206, a next-generation antibody dru...
